Advertisement

Picture Mologen AG Investing in Power of Immunotherapy Middle 600x60px
Organisation › Details

Analytik Jena AG

Analytik Jena AG (ISIN: DE0005213508, market segment: Prime Standard, Stock market symbol: AJA) generated Group revenue of EUR 28.8 m (previous year 12 months: EUR 121.3 m) from October 1 to December 31, 2014. In the instrument business, total revenue amounted to EUR 24.4 m (previous year 12 months: EUR 99.7 m). Group revenue included the revenue recognized in the project business of our AJZ Engineering subsidiary, which totaled EUR 4.3 m (previous year 12 months: EUR 21.6 m) at the end of the shortened financial year. Analytik Jena’s export ratio amounted to 76.8 % (previous year: 79.3 %). Analytik Jena recorded order entry of EUR 23.1 m in the instrument business. The Group concluded the financial year with earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR -9.7 m (previous year: EUR -1.3 m) with an EBITDA margin of -33.9 % (previous year: -1.0 %). Earnings before interest and taxes (EBIT) amounted to EUR -11.6 m (previous year: EUR -6.2 m). The unsatisfactory earnings development is also attributable to the continued weak operating business as Analytik Jena was unable to offset higher selling, administrative, and R&D costs resulting from the acquisitions in the past two financial years with any corresponding increases in revenue in the instrument business. The operating result was negatively affected particularly by sustained weak revenue in all three business units of the instrument business and respective losses in Life Science, Optics, and the Project Business. The result was additionally affected by planned restructuring measures in the Life Science business unit realized by the creation of provisions as one-time effects. They include expected costs for the closure of the sepsis diagnostics area and the depreciation of a shareholdings' book values. At the end of the financial year, Analytik Jena recorded a consolidated net loss for the year of EUR -13.0 m (previous year: EUR -9.2 m). Earnings per share amounted to EUR -1.31 (previous year: EUR -1.21). In the past shortened financial year, Analytik Jena recorded positive operating cashflow of EUR 1.2 m (previous year: EUR -5.6 m). As of December 31, 2014, the Group had a total of 1,102 employees, including 36 interns (previous year: 1,098 employees, including 35 interns), or nearly as many employees as on the previous balance sheet date. *

 

Period Start 1990-01-01 splitoff
  Group Endress+Hauser (Group)
  Predecessor Carl Zeiss Jena GmbH
Products Industry laboratory equipment and instruments
  Industry 2 thermocycler (PCR thermal cycler)
Persons Person Krauss, Ulrich (Endress+Hauser 201610– CEO at Analytik Jena joined 201511 before Carl Zeiss)
  Person 2 Berka, Klaus (Analytik Jena 200702 Chairman Executive Board)
     
Region Region Jena
  Country Germany
  Street 1 Konrad-Zuse-Str.
  City 07745 Jena
  Tel +49-3641-77-70
  Fax +49-3641-77-9279
    Address record changed: 2008-12-07
     
Basic data Employees F: 1,001 to 5,000 (2014-12-31)
  Currency EUR
  Annual sales 97,700,000 (revenue, consolidated (2012/13) 2013-09-30)
  Profit -3,100,000 (2013-09-30)
  Cash 4,500,000 (2013-06-30)
     
    * Document for »About Section«: Analytik Jena AG. (3/5/15). "Press Release: Analytik Jena Closes Three Month Shortened Financial Year 2014 Negatively". Jena.
     
   
Record changed: 2016-09-20

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Endress+Hauser (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO Europe 2016 BEU Cologne November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Mologen AG Investing in Power of Immunotherapy Middle 120x180px Picture EuropaBio European Biotech Week 2016 September 120x180px Picture EBD Group BIO Europe 2016 BEU Cologne November 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px